Treatment Satisfaction, Efficacy, and Safety of Delgocitinib Ointment for Atopic Dermatitis‐Induced Rash on the Face and Neck: Efficacy at Reducing Local Side Effects of Topical Steroid and Tacrolimus Ointment
The Journal of Dermatology · 2025
DOI: 10.1111/1346-8138.17817 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift The Journal of Dermatology, 2025. Verfasst von Masatoshi Abe und 5 weiteren Autor:innen. Beteiligte Einrichtung: Kojinkai Sapporo Skin Clinic, Sapporo, Japan. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Pyrimidines, Exanthema. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Torii Pharmaceutical.
Abstract (Originalsprache)
This open‐label, single‐arm, multicenter clinical study evaluated the treatment satisfaction, efficacy, and safety of 0.5% delgocitinib ointment twice daily for 12 weeks, applied to face/neck lesions caused by ≥ 3 months use of topical steroids or tacrolimus ointment in patients with atopic dermatitis (AD). The primary endpoint was change in treatment satisfaction (Treatment Satisfaction Questionnaire for Medication‐9 [TSQM‐9]). Secondary endpoints included changes in modified Eczema Area and Severity Index (mEASI) and EASI scores, the numerical rating scale (NRS) for pruritus, the severity of side effects, skin condition at target lesions, disease control (Atopic Dermatitis Control Tool [ADCT]), and preference for delgocitinib ointment (Patient Preference Questionnaire [PPQ]). Overall, 38 patients (mean age 40 years) with a duration of AD of 30.7 years were included in the study. Scores of TSQM‐9 for global satisfaction (Week 0: 58.8 ± 14.7; Week 4: 68.5 ± 16.6; Week 12: 73.2 ± 16.0), effectiveness (57.0 ± 14.1; 67.0 ± 12.6; 70.9 ± 13.4), and convenience (64.9 ± 15.0; 73.6 ± 12.7; 76.1 ± 13.6) (all cases p < 0.01), mEASI (Week 0: 1.31; Week 12: 0.68, p < 0.001) and NRS (4.53; 2.71, p < 0.001) scores, and ADCT (8.3; 5.6, p < 0.01) were improved significantly. Compared with that at Week 0, the incidence of ≥ mild skin atrophy, telangiectasia, and skin irritation decreased. The PPQ showed that approximately 80% of patients rated all queries as “strongly agree” or “agree.” In addition, skin conditions were significantly improved for all items (dryness, feel, firmness/elasticity, and appearance) at 1–2 weeks and 12 weeks ( p < 0.001). The present results demonstrate that delgocitinib ointment might be an effective option for switching treatment for face/neck AD in patients with skin lesions, or for those who are concerned about the development of side effects related to steroids or tacrolimus. Trial Registration: Japan Registry of Clinical Trials (jRCTs031230063)
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Kojinkai Sapporo Skin Clinic, Sapporo, Japan.
- Igarashi Dermatology Higashigotanda, Tokyo, Japan.
- Torii Pharmaceutical Co., Ltd., Tokyo, Japan.
- Department of Dermatology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
- Department of Dermatology, Nippon Medical School, Tokyo, Japan.
ORCID-Profile: Masatoshi Abe, Atsuyuki Igarashi, Hiroyuki Toyama, Kenji Kabashima, Hidehisa Saeki
Förderung
- Torii Pharmaceutical
Zitieren
APA
Abe, M., Igarashi, A., Kitajima, H., Toyama, H., Kabashima, K., & Saeki, H. (2025). Treatment Satisfaction, Efficacy, and Safety of Delgocitinib Ointment for Atopic Dermatitis‐Induced Rash on the Face and Neck: Efficacy at Reducing Local Side Effects of Topical Steroid and Tacrolimus Ointment. The Journal of Dermatology. https://doi.org/10.1111/1346-8138.17817
Vancouver
Abe M, Igarashi A, Kitajima H, Toyama H, Kabashima K, Saeki H. Treatment Satisfaction, Efficacy, and Safety of Delgocitinib Ointment for Atopic Dermatitis‐Induced Rash on the Face and Neck: Efficacy at Reducing Local Side Effects of Topical Steroid and Tacrolimus Ointment. The Journal of Dermatology. 2025. doi:10.1111/1346-8138.17817
BibTeX
@article{Abe2025,
author = {Abe, Masatoshi and Igarashi, Atsuyuki and Kitajima, Hiroyuki and Toyama, Hiroyuki and Kabashima, Kenji and Saeki, Hidehisa},
title = {Treatment Satisfaction, Efficacy, and Safety of Delgocitinib Ointment for Atopic Dermatitis‐Induced Rash on the Face and Neck: Efficacy at Reducing Local Side Effects of Topical Steroid and Tacrolimus Ointment},
journal = {The Journal of Dermatology},
year = {2025},
doi = {10.1111/1346-8138.17817}
}
EUVIMED